EDENT1FI (European early-detection consortium)
EDENT1FI consortium — co-led by Helmholtz Munich and KU Leuven, funded by the Innovative Health Initiative (Horizon Europe)
The plumbing that turns national screening studies into a European programme.
What it is
The harmonised backbone of European screening for presymptomatic type 1 diabetes (T1D). EDENT1FI is not a test you order — it is the shared infrastructure that national screening efforts plug into: one published master protocol, one capillary finger-prick islet-autoantibody panel, one staging and monitoring pathway, run by 27 partner organisations across 13 countries. It had screened 100,000 of a planned 220,000 children by March 2026, at roughly 6,500 a month. It is how a country goes from "a study" to "a programme".
Editorial review: .
Most recent recorded citation date: 2026-03-16. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Predictive value: Uses the standard, well-validated capillary islet-autoantibody panel (IAA, GAD65, IA-2, ZnT8) and the consensus staging model, harmonised across every site by a published master protocol — aiming for a positive result to mean the same thing in Lisbon as in Munich. The underlying biology is as reliable as autoantibody screening gets; what EDENT1FI adds is consistency, not a new predictor.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Ages 1-17, across 13 countries — but it is an EU-funded research consortium, not a reimbursed national health serviceApproval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 84 × 25 + 82 × 25 + 86 × 20 + 85 × 15 + 58 × 15 = 8015; divide by total weight 100. Unrounded weighted result: 80.15.
Uses the standard, well-validated capillary islet-autoantibody panel (IAA, GAD65, IA-2, ZnT8) and the consensus staging model, harmonised across every site by a published master protocol — aiming for a positive result to mean the same thing in Lisbon as in Munich. The underlying biology is as reliable as autoantibody screening gets; what EDENT1FI adds is consistency, not a new predictor.[1]
Screen-positive children enter a harmonised monitoring pathway, which is intended to reduce ketoacidosis at diagnosis. And a positive result now leads somewhere concrete across Europe: teplizumab was approved in the EU in January 2026 to delay stage 3 T1D in children aged 8 and over. Below age 8 it still buys monitoring, education and preparation rather than a drug.[2]
General population, ages 1-17, across 13 European countries — not relatives-only, which matters because most new T1D occurs in children with no family history. 100,000 of a 220,000 target screened by March 2026, at about 6,500 a month.[2]
A capillary finger-prick, not a venous draw — deliberately, because the whole design goal is a test that can be taken during ordinary paediatric care. Only the small fraction who screen positive need confirmatory and glucose testing.[1]
It is a time-limited EU-funded research consortium rather than a reimbursed health service — its explicit purpose is to hand each country a working national programme before the funding ends. Whether screening survives in each country is a national decision that has not been made in most of them.[1]
The full picture
Most of the screening programmes on this site are national efforts: Fr1da in Bavaria, ELSA in the UK, D1Ce Screen in Italy. EDENT1FI is the layer underneath them. It is a consortium — 27 partner organisations across 13 European countries, co-led by Helmholtz Munich and KU Leuven — whose job is to make screening for presymptomatic type 1 diabetes (T1D) work the same way everywhere, and to leave behind national programmes that keep running once the project money stops.2
You cannot "get an EDENT1FI test". You get a national screening test that is built to the EDENT1FI standard. That distinction is the whole point of it.
What the master protocol actually standardises
A master protocol is a single study design that many sites run in parallel, rather than each country inventing its own. EDENT1FI published one in BMJ Open in 2025, and it fixes the things that would otherwise make cross-country results incomparable:1
- The sample: a capillary finger-prick, not a venous draw — chosen so the test can happen during ordinary paediatric care instead of a hospital visit.
- The panel: islet autoantibodies — IAA, GAD65, IA-2 and ZnT8. Two or more confirmed autoantibodies define presymptomatic T1D.
- The staging: the consensus model — stage 1 (autoantibodies, normal glucose), stage 2 (autoantibodies plus abnormal glucose), stage 3 (clinical diabetes).
- What happens next: a harmonised monitoring and education pathway for the families who screen positive.
That last item is the one people underrate. Finding a child with two autoantibodies is only useful if somebody knows what to do on Monday morning. A screening result with no follow-up pathway attached is a source of anxiety, not a source of safety. Europe now also has a published consensus roadmap for exactly that — how to screen, and how to monitor afterwards.3
Where it has got to
As of 16 March 2026, EDENT1FI had screened 100,000 children and adolescents against a planned target of 220,000, running at roughly 6,500 a month.2 Ages 1 to 17, general population — not relatives-only, which matters, because the majority of new T1D arises in children with no family history at all.
The consortium reports that it has established new screening programmes in Czechia, Poland and Portugal, and strengthened existing ones in Germany, Italy, the UK, Denmark and Sweden.2 Those are two genuinely different achievements. Strengthening Bavaria's Fr1da is incremental. Standing up a first-ever national screening effort in a country that had none is the thing that changes a child's odds.
One number we deliberately do not give you: how many early-stage cases EDENT1FI has found. The consortium's own announcement of the 100,000 milestone does not report a yield, and we are not going to infer one from other programmes' rates and present it as theirs.2 For a sense of the scale involved, Fr1da found presymptomatic T1D in about 0.31% of the children it screened — but that is Fr1da's figure, in Bavaria, and it is not EDENT1FI's.
Why a positive result now means more than it used to
Screening only pays off if something follows it. Two things now do.
The first is DKA prevention. Diabetic ketoacidosis is the dangerous metabolic crisis in which many children are still diagnosed with T1D; screening programmes that find children early and monitor them have reduced the risk of DKA at diagnosis. This benefit applies to screened children and it requires no drug.
The second is teplizumab, which was approved in the EU in January 2026 to delay progression to clinical T1D in children aged 8 and over with presymptomatic disease.2 So a European family whose eight-year-old screens positive at stage 2 now has an actual therapeutic option, not just a warning. Be precise about the limit, though: below age 8 there is no approved disease-modifying drug, and for those children screening buys monitoring, education and a gentler diagnosis — which is a lot, but it is not a drug.
The honest limitation: this is a grant, not a health service
EDENT1FI is an EU-funded research consortium with a defined end date. It is not reimbursed care, and no child in Europe has a right to a T1D screen because EDENT1FI exists. That is why its access score here is middling despite the test itself being free and easy: the entitlement is missing.
Read that as the consortium's own theory of itself. The stated purpose is to leave behind working national programmes — which is why "established new programmes in Czechia, Poland and Portugal" is the metric that matters more than the headcount. The only European country where screening is a legal entitlement rather than a project is Italy, under Law 130/2023. Everywhere else, the question that decides whether any of this survives is national, political, and still open: when the grant ends, does the health ministry pick up the bill?
A hundred thousand children screened is a real achievement. The programme that outlives the funding is the one that counts.
What's next for this
- →The remaining ~120,000 of the 220,000-participant target to be screened
- →Hand-off of working national screening programmes to member states before the EU funding ends — the real test of whether any of this outlives the grant
Sources
- [1]EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents · Peer-reviewed study · 2025-01-01 — The shared protocol every participating site works from — capillary autoantibody panel, staging, and the monitoring pathway after a positive result.
Hoffmann L, et al. EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents. BMJ Open (2025).
- [2]100,000 Participants Screened for Early-Stage Type 1 Diabetes in the EDENT1FI Project · Science journalism · 2026-03-16 — Source of the 100,000/220,000 figures, the ~6,500/month rate, the 27 partners across 13 countries, and the new-vs-strengthened country split. It does not report how many early-stage cases have been found, so we quote no yield figure.
Helmholtz Munich. 100,000 Participants Screened for Early-Stage Type 1 Diabetes in the EDENT1FI Project (16 March 2026).
- [3]An international consensus on screening and monitoring early-stage type 1 diabetes - a roadmap to European implementation · Peer-reviewed study · 2026-03-12
Hussain S, et al. An international consensus on screening and monitoring early-stage type 1 diabetes: a roadmap to European implementation. Diabetes, Obesity and Metabolism (2026).